REGENXBIO Faces Critical Setback as FDA Halts Gene Therapy Trials Following Pediatric Brain Tumor Discovery

In a sobering reminder of the complex safety challenges facing gene therapy development, REGENXBIO announced on January 28, 2026, that the FDA has placed clinical holds on two of its most promising investigational therapies following the discovery of a brain tumor in a pediatric patient. The regulatory action affects both RGX-111 for Hurler syndrome and RGX-121 for Hunter syndrome, casting uncertainty over treatments that were poised to address critical unmet medical needs in rare pediatric diseases.

The clinical hold stems from a single case involving a five-year-old participant who developed an intraventricular CNS tumor four years after receiving RGX-111 treatment for mucopolysaccharidosis type I (MPS I), also known as Hurler syndrome. The tumor was discovered during a routine brain MRI of an otherwise asymptomatic patient, highlighting the importance of long-term safety monitoring in gene therapy programs.

Preliminary Analysis Reveals Concerning Integration Event

What makes this case particularly significant is the preliminary genetic analysis of the resected tumor, which detected an adeno-associated virus (AAV) vector genome integration event associated with overexpression of PLAG1, a proto-oncogene known to be susceptible to chromosomal rearrangements. This finding raises fundamental questions about the long-term safety profile of AAV-based gene therapies, particularly those delivered directly to the central nervous system.

The discovery is especially concerning given that AAV vectors have long been considered among the safest gene therapy delivery systems due to their typically non-integrating nature. While AAV integration events are rare, this case demonstrates that they can occur and potentially contribute to oncogenic transformation, particularly when involving genes like PLAG1 that are known drivers of certain cancers.

Importantly, REGENXBIO emphasizes that causality has not been established, and the investigation to determine whether this serious adverse event is drug-related remains ongoing. The affected participant continues to be asymptomatic with positive developmental advancements noted by the treating physician, suggesting that the tumor was caught early and successfully treated.

Collateral Impact on Hunter Syndrome Program

Perhaps most controversial is the FDA's decision to also place RGX-121 on clinical hold, despite the tumor occurring in a different therapy for a different indication. The agency cited "similarities in products, study populations, and shared risk between the clinical studies" as justification for the broader hold, a decision that has drawn sharp criticism from REGENXBIO leadership.

"We are surprised by FDA's decision to place our RGX-121 programme on hold while the investigation of this single, inconclusive incident in RGX-111 continues," said Curran Simpson, President and CEO of REGENXBIO. "These are separate therapies, and the positive safety profile of RGX-121 in more than 30 patients treated, including those dosed nearly seven years ago, remains unchanged."

The company's frustration is understandable given that RGX-121 was approaching a critical regulatory milestone, with an FDA approval decision originally scheduled for February 8, 2026. The therapy had already received multiple regulatory designations including Orphan Drug, Rare Pediatric Disease, Fast Track, and Regenerative Medicine Advanced Therapy status, reflecting both the significant unmet need and the therapy's potential to address it.

Market Response Reflects Broader Gene Therapy Concerns

The market's reaction to the clinical hold announcement was swift and severe, with REGENXBIO shares plummeting approximately 32% in premarket trading following the news. The dramatic sell-off reflects not only the immediate impact on the company's near-term prospects but also broader investor concerns about gene therapy safety that have periodically surfaced throughout the field's development.

The timing of the hold is particularly challenging for REGENXBIO, coming just days before the scheduled FDA decision on RGX-121. The company had been positioning itself as a leader in AAV-based therapies for rare diseases, with a pipeline that includes treatments for Duchenne muscular dystrophy and various retinal conditions in partnership with major pharmaceutical companies.

Wall Street analysts have characterized the clinical hold as an overreaction, with several maintaining buy ratings while acknowledging the near-term uncertainty. Stifel analysts noted that the hold likely delays the PDUFA date for RGX-121 but emphasized the therapy's distinct safety profile and the absence of reported tumors in its 32-patient treatment history.

Broader Implications for Gene Therapy Field

This regulatory action comes at a time when the gene therapy field has been grappling with various safety challenges across multiple programs and companies. The discovery of a potential AAV integration-related tumor adds another layer of complexity to an already challenging regulatory environment, particularly for therapies targeting the central nervous system.

The case highlights the critical importance of long-term safety monitoring in gene therapy programs, especially those involving pediatric populations where the consequences of adverse events can be particularly devastating. The fact that the tumor was discovered four years post-treatment underscores the need for extended follow-up periods that may span decades rather than years.

For the broader AAV gene therapy field, this case will likely prompt renewed scrutiny of integration risks and may influence regulatory requirements for future programs. While AAV vectors remain among the safest gene therapy delivery systems available, this incident demonstrates that no therapeutic approach is without risk, particularly when targeting critical organs like the brain.

Patient Community Impact

The clinical holds have profound implications for patients and families affected by MPS I and MPS II, conditions that cause progressive deterioration and typically result in death during childhood or adolescence without effective treatment. Current therapeutic options are limited and often inadequate, making the potential availability of gene therapies particularly crucial for these communities.

For MPS II patients specifically, the delay in RGX-121 approval means continued reliance on enzyme replacement therapies that cannot cross the blood-brain barrier to address the neurological manifestations of the disease. As Simpson noted, "continued delay means continued neurodevelopmental decline in boys with MPS II," highlighting the urgent medical need that these therapies were designed to address.

The patient advocacy community now faces the difficult balance between supporting continued development of potentially life-saving therapies while ensuring that safety remains the paramount concern. The discovery of this tumor case will likely intensify discussions about acceptable risk-benefit ratios in rare pediatric diseases where treatment options are severely limited.

Looking Ahead

REGENXBIO has indicated that it has not yet received the full clinical hold letter from the FDA and awaits additional details from the agency. The company will likely need to provide comprehensive responses to FDA questions about both the specific tumor case and the broader safety implications for its AAV platform before the holds can be lifted.

The resolution of this situation will have implications far beyond REGENXBIO's immediate prospects. How the FDA and the company navigate this safety signal will likely establish precedents for how similar cases are handled in the future and may influence the development strategies of other gene therapy companies working with AAV vectors.

For now, the gene therapy field faces another reminder that despite remarkable scientific advances, the path from laboratory to patient remains fraught with challenges that require careful navigation, rigorous safety monitoring, and a commitment to putting patient welfare above all other considerations. As the investigation into this tumor case continues, the entire field will be watching closely to understand the implications for the future of AAV-based gene therapies.